Rare Disease Trial, Recruiting NCT07372833 Sponsor: Erasmus Medical Center Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT07372833
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a genetic change in one of the CAMK2 genes that has been confirmed or is likely to be harmful
  • You are willing to have your information recorded anonymously in a national or international database

Who may not be able to join:

  • You have a genetic change in the CAMK2 gene that is classified as a "Variant of Unknown Significance" (meaning scientists are not yet sure if the change is harmful) — in these cases, additional laboratory testing would need to be done first before you could be considered

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Danielle CM Veenma, MD PhD, Erasmus Medical Center

Phone: 010-7037815

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Erasmus Medical Center
Registry
ClinicalTrials.gov
Start date
9 February 2021
Est. completion
1 January 2040

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Age of milestone achievement; Presence of seizures; Adaptive Behavior Assessment System 3 (ABAS-3) score; Social Responsiveness Scale, Second Edition (SRS-2) total score; Aberrant Behavior Checklist (ABC) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov